timothy sykes logo
MRNA Jumps As FDA Clears mFLUSIVA Flu Vaccine Thumbnail
G Google News

MRNA Jumps As FDA Clears mFLUSIVA Flu Vaccine

JACK KELLOGG•UPDATED AUG. 19, 2026, 7:47 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Moderna Inc. stocks have been trading up by 83.01 percent, driven mainly by breakthrough mRNA vaccine progress and approvals.

Key Takeaways For MRNA Traders

  • FDA approval of mFLUSIVA gives Moderna a fourth U.S. product and sets up a new flu franchise launch for the 2026–27 season, with additional reviews in Australia, Canada, and Europe.
  • Q2 2026 brought modest revenue growth but a large net loss, even as management tightened expense guidance and reiterated a target of up to 10% revenue growth from 2025 levels.
  • A key norovirus Phase 3 miss underscored clinical risk, but oncology and rare disease programs remain on track with pivotal data expected in 2026.
  • A CEPI‑backed Phase 1 trial for Bundibugyo ebolavirus (mRNA‑1469) extends Moderna’s global health reach with external funding support.
  • Goldman Sachs and Citi both raised MRNA price targets, to $67 and $60, maintaining Neutral ratings that signal cautious optimism, not full-on bullishness.

Candlestick Chart

Live Update At 07:47:08 EDT: On Wednesday, August 19, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 83.01%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA’s chart has been a real rollercoaster. Over the last few weeks, Moderna has pushed from the mid‑$50s to the low‑$60s, with recent daily closes clustering around $63. That steady grind higher tells traders that dip buyers are active, even as volatility stays elevated.

Intraday, the stock can move like a low-float runner. A recent premarket session saw MRNA spike from the high‑$60s to above $110 in under an hour, then consolidate just above $115. That kind of range is a magnet for momentum trading, but it punishes anyone who overstays a move.

Fundamentals still show a company in build‑out mode, not a cash machine. Q2 revenue was about $1.94B, but Moderna posted a net loss of $782M and operating cash outflow of $526M. Margins are deep in the red, with EBIT margin near ‑139% and free cash flow at roughly ‑$563M.

More Breaking News

On the positive side, MRNA carries low debt, strong liquidity (current ratio around 2.3), and about $5.1B in cash and short‑term investments. For traders, that balance sheet buys time for the pipeline to mature while the stock trades as a high‑beta biotech story rather than a steady earnings play.

Why Traders Are Watching MRNA Now

The key driver right now is the U.S. FDA approval of Moderna’s mFLUSIVA flu vaccine for adults 50+. This gives MRNA its fourth approved product in the U.S. and fifth globally, and it finally moves the company beyond being a one‑product COVID story. The launch is slated for the 2026–27 respiratory virus season, but traders are already pricing in the narrative shift.

The approval also clears a major regulatory overhang. For months, MRNA trading has been tied to whether its flu program could prove it was more than a science project. With the green light in hand, the conversation shifts toward how big the flu opportunity can get, and how quickly. Additional reviews underway in Australia, Canada, and Europe add a global angle that momentum traders love, because each new country approval becomes another headline catalyst.

At the same time, the Q2 2026 earnings print reminded everyone that this is still a loss‑making biotech. MRNA reported a narrower loss of $1.97 per share and slight year‑over‑year revenue growth, beating expectations on both revenue and EPS. Yet the stock swung hard around the release — down about 4% premarket in one read, up more than 3% after in another. That whipsaw reaction tells you sentiment on Moderna is divided and very headline‑driven.

Guidance matters here. Management cut its 2026 cost‑of‑sales outlook to $1.7B from $1.8B and is targeting up to 10% revenue growth from 2025 levels, with more than half of second‑half 2026 revenue expected in Q3. For active traders, that concentration makes Q3 2026 a prime catalyst window. Add in pivotal readouts for the intismeran oncology and rare‑disease programs, plus the CEPI‑backed Ebola trial starting in Canada, and MRNA is packed with news flow that favors nimble, catalyst‑focused trading strategies.

Conclusion

For traders who thrive on volatility and catalysts, MRNA is back on the radar in a big way. The mFLUSIVA approval is not a small add‑on; it is a second major commercial pillar that supports Moderna’s respiratory vaccine strategy for years. The company is still burning cash and posting heavy losses, but its balance sheet and global flu roadmap give it room to execute.

The pipeline picture is mixed but still supports an active trading thesis. The norovirus Phase 3 stumble is a reminder that not every bet pays off, yet the high‑profile oncology program with Merck and rare‑disease assets are tracking toward pivotal data in 2026. Those readouts, together with the staged global rollout of mFLUSIVA, give MRNA a steady drumbeat of potential chart‑moving events.

Wall Street is adjusting to this setup. Goldman Sachs lifting its target to $67 and Citi to $60, both with Neutral ratings, shows analysts see more upside than they did earlier in the year, but still respect the risk. Price targets are climbing, not screaming higher.

For the Sykes‑style crowd, the game plan is familiar: treat MRNA like a catalyst‑rich trading vehicle, not a set‑and‑forget holding. As Tim Sykes likes to say, “The best traders aren’t trying to predict five years out — they’re focused on the next key catalyst, the chart, and cutting losses fast.” As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.”. MRNA’s story now lines up perfectly with that mindset, making it a name to study closely, not blindly chase.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”